Perinatal deaths after sildenafil treatment of fetal growth restriction raise the issue of safety in randomised clinical trials
- 7 March 2019
- journal article
- editorial
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 28 (4) , 437-438
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Clinicians should stop prescribing sildenafil for fetal growth restriction (FGR): comment from the STRIDER ConsortiumUltrasound in Obstetrics & Gynecology, 2018
- Trial of Viagra for fetal growth restriction is halted after baby deathsBMJ, 2018
- Maternal sildenafil for severe fetal growth restriction (STRIDER): a multicentre, randomised, placebo-controlled, double-blind trialThe Lancet Child & Adolescent Health, 2018
- STRIDER (Sildenafil TheRapy in dismal prognosis early onset fetal growth restriction): an international consortium of randomised placebo-controlled trialsBMC Pregnancy and Childbirth, 2017
- Sildenafil in Pregnancy: A Systematic Review of Maternal Tolerance and Obstetric and Perinatal OutcomesFetal Diagnosis and Therapy, 2016
- Intrauterine growth restriction – part 2The Journal of Maternal-Fetal & Neonatal Medicine, 2016
- Clinical trials in childrenBritish Journal of Clinical Pharmacology, 2015
- Data sources on drug safety evaluation: a review of recent published meta-analysesPharmacoepidemiology and Drug Safety, 2011
- Adverse drug reactions: definitions, diagnosis, and managementThe Lancet, 2000